CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Samsung Bioepis Co., Ltd. vs. Alexion Pharmaceuticals, Inc. et al.

๐Ÿ“ก 5G SEP โ€ข ETSI Declared

Explore the PTAB proceeding IPR2023-00999 filed by Samsung Bioepis Co., Ltd. on 2023-05-31. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2023-00999

Filing Date

2023-05-31

Accorded Filing Date

2023-05-31

Institution Decision Date

2023-12-08

Last Modified Date

2024-09-04

Proceeding Type

IPR

Termination Date

2024-09-04

Trial Status

Terminated-Settled

Parties & Counsel

Petitioner

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 15260888
Respondent Patent Number 9725504
Legal Expiration Date
2036-09-09 Active (9.8 yrs remaining)
Injunction Viability (35 U.S.C. ยง 283) Active Threat
Respondent Inventor Leonard BELL et al
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

2 Total

Proceeding Status

Terminated-Settled

Administrative Patent Judges (APJ Panel)

Panel assignment tracked upon institution decision entry

Board Decisions & Rulings (2)

Settled After Institution 2024-09-04
Termination Decision: Post-DI Settlement
35 USC 318, 37 CFR 42.72, 37 CFR 42.74, 35 USC 317
Institution Granted 2023-12-08
Institution Decision: Grant
35 USC 312, 35 USC 314, 37 CFR 42.100, 35 USC 325

Address and Attorney/Agent Information

61 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
Customer Number 20306
Address 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
28399 Daniel Boehnen +1 312-913-0001
30130 Bradley Hulbert +1 312-913-0001
30243 Paul Berghoff +1 312-913-0001
32565 Grantland Drutchas +1 312-913-2121
32784 Steven Sarussi +1 312-913-0001
35285 Emily Miao +1 312-913-0001
35303 Kevin Noonan +1 312-913-0001
35818 Lawrence Aaronson +1 312-913-0001

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 10 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts Counterparts in force
๐Ÿ›๏ธ
USPTO PTAB Trials 7 proceedings
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (10): ๐Ÿ‡บ๐Ÿ‡ธ US ๐ŸŒ PCT
Parallel Proceedings Across Jurisdictions (7 found):
PTAB: 7
USPTO PTAB Trial 2023-06-16
IPR2023-01070

Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.

U.S. Continuation Sibling (10703809)
Status: Terminated-Settled
USPTO PTAB Trial 2023-06-16
IPR2023-01069

Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.

U.S. Continuation Sibling (10590189)
Status: Terminated-Settled
USPTO PTAB Trial 2023-05-31
IPR2023-00998

Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.

U.S. Continuation Sibling (9718880)
Status: Terminated-Settled
USPTO PTAB Trial 2023-05-18
IPR2023-00933

Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.

U.S. Continuation Sibling (9732149)
Status: Terminated-Settled
USPTO PTAB Trial 2019-02-28
IPR2019-00740

Amgen Inc. v. Alexion Pharmaceuticals, Inc.

U.S. Continuation Sibling (9718880)
Status: Terminated-Settled
USPTO PTAB Trial 2019-02-28
IPR2019-00739

Amgen, Inc. v. Alexion Pharmaceuticals, Inc.

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2019-02-28
IPR2019-00741

Amgen, Inc. v. Alexion Pharmaceuticals, Inc.

U.S. Continuation Sibling (9732149)
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP โ€ข ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 5G NR Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Samsung

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

โœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
โœ“ Right to demand global FRAND portfolio determination.
โœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Proceeding Documents

183
27

Termination Decision: Post-DI Settlement TERMINATE

2024-09-04 FILING PARTY: BOARD
25

Joint Motion to Terminate MOTION

2024-08-30 FILING PARTY: PATENT OWNER
26

Joint Motion to Treat Settlement Agreement as Confidential MOTION

2024-08-30 FILING PARTY: PATENT OWNER
24

ORDER Setting Oral Argument ORDER

2024-08-26 FILING PARTY: BOARD
22

Patent Owner's Request for Oral Argument NOTICE

2024-08-07 FILING PARTY: PATENT OWNER

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc